FIELD: chemistry.SUBSTANCE: invention relates to application of compounds of formula I, where R1 represents hydrogen atom, C1-7-alkyl, C1-7-alkoxy, C1-7-alkyl, substituted with halogen atom, C1-7-alkoxy, substituted with halogen atom, halogen atom, cyano, nitro, hydroxy, C(O)O-C1-7-alkyl, S(O)2-C1-7-alkyl, C(O)OCH2-phenyl, OCH2-phenyl, tetrazol-1-yl, phenyl, possibly substituted with halogen atom, or represents phenyloxy, possibly substituted with halogen atom, or represents benzyl, possibly substituted with halogen atom, or represents benzyloxy, possibly substituted with halogen atom； in case, when n>；1, R1 substituents can be similar or different； X represents -O-(CH2)2-, -O-CHR"-CH2-, -O-CH2-CHR', -O-CR"2-CH2-, -(CH2)2-CHR'-, -CHR'-(CH2)2-, -CR"2-(CH2)2-, -CH2-CHR'-CH2-, -CH2-CR"2-CH2-, -CHR"-O-CH2-, -CR"2-O-CH2-, -CF2(CH2)2-, -CR"2-CH2-, -SiR"2-(CH2)2-, -S-(CH2)2-, -S(O)2-(CH2)2-, -(CH2)4-, -CH2-O-(CH2)2-, formula (a) or (b), where m has value 0, 1, 2 or 3； R' represents C1-7-alkyl, C1-7-alkoxy or C1-7-alkyl, substituted with halogen atom； R" represents C1-7-alkyl or C1-7-alkyl, substituted with halogen atom； R2 represents hydrogen atom or C1-7-alkyl； Y represents phenyl, naphthyl, C3-6-cycloalkyl or pyridin-2- or 3-yl, pyrimidin-2-yl or quinolin-6 or 7-yl； n has value 1, 2 or 3； or pharmaceutically acceptable salt of acid attachment in manufacturing medication for treatment anxiety disorders, bipolar disorder, stress-induced disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson disease, neurodegenerative disorders, Alzheimer's disease, epilepsy and migraine. Invention also relates to compounds of formula I, where R1 represents hydrogen atom, C1-7-alkyl, C1-7-alkoxy, C1-7-alkyl, substituted with halogen atom, C1-7-alkoxy, substituted with halogen atom, halogen atom, cyano, nitro, hydroxy, C(O)O-C1-7-alkyl, S(O)2-C1-7-alkyl, C(O)OCH2-phenyl, OCH2phenyl, tetrazol-1-yl, phenyl, possibly substituted with halogen atom, or represents phe
